Periprocedural Infarction vs. Spontaneous Infarction: Prognostic Significance 

Original title: Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention–Related Myocardial Infarction. Reference: Sergio Leonardi, MD et al. Journal of the American College of Cardiology Vol. 60, No. 22, 2012

Clinical significance of myocardial infarction (MI) associated to coronary angioplasty is a controversial issue worldwide. Most of research on coronary disease includes it as a primary end point weighed against spontaneous MI.

The aim of this study was to compare periprocedural MI vs. spontaneous MI. It analyzed data from 9,087 patients enrolled in two trials that assessed Non ST Segment Elevation Acute Coronary Syndrome (EARLY-ACS and SYNERGY): among these, 893 periprocedural MI and 298 spontaneous MI occurred, and ratios for death at 12 months were compared.

Authors defined periprocedural MI as CK-MB more than 3 times the ULN (upper limit of normal). Adjusted hazard ratios for 1-year death were 1.39 (95% CI: 1.01 to 1.89) for periprocedural MI vs. 5.37 (95% CI: 3.9 to 7.38) for spontaneous MI. In determining the CK-Mb threshold for periprocedural MI to achieve the same prognosis as spontaneous MI, it was observed that elevations of 27 times the ULN were necessary for this to happen.

Conclusion 

The definition of periprocedural infarction used in clinical trials is poorly associated to events, compared to spontaneous infarction.

Editorial Comment:

This study confirms an assumption based on intuition, that cardiac enzymes elevation after angioplasty does not have the same prognosis than Type 1 MI. Further evaluation is required to confirm these results using the new definition of periprocedural MI (a 5 times increase of troponin levels with clinical or electrical signs or ischemia image). Despite the above observations, this study is good news for interventional cardiologists.

Courtesy of María Sol Andres, MD
Hospital Universitario
Fundación Favaloro – Argentina

Dra. María Sol Andrés para SOLACI.ORG

More articles by this author

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...